Description: bioMérieux S.A. develops and produces in vitro diagnostic solutions for the diagnosis of infectious diseases in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers systems, which use biological samples to diagnose infectious diseases, cardiovascular pathologies, and various cancers; and microbiological testing of manufacturing primarily for food, pharmaceutical, cosmetics, and veterinary sectors. It serves clinical and hospital laboratories, physicians, blood banks, and industrial control laboratories. The company was formerly known as B-D Mérieux. bioMérieux S.A. was founded in 1963 and is headquartered in Marcy l'Etoile, France. bioMérieux S.A. is a subsidiary of Institut Mérieux SA.
Home Page: www.biomerieux.com
376 Chemin De l’Orme
Marcy l'Étoile,
69280
France
Phone:
33 4 78 87 20 00
Officers
| Name | Title |
|---|---|
| Mr. Alexandre Merieux | Chairman & CEO |
| Mr. Pierre Boulud | Chief Operating Officer of Clinical Operations |
| Mr. Frederic Beseme | Head of CSR |
| Mr. Guillaume Bouhours | Exec. VP of Purchasing and Information Systems & CFO |
| Sylvain Morgeau | Investor Relations |
| Ms. Valerie Leylde | Exec. VP of HR, Communications & CSR |
| Mr. François Lacoste | Exec. VP of R&D |
| Mr. Mark Miller | Exec. VP of Medical Affairs |
| Mr. Pierre Charbonnier | Exec. VP of Quality, Manufacturing & Supply Chain |
| Mr. Yasha Mitrotti | Exec. VP of Industrial Microbiology |
Exchange: PA
Country: FR
Currency: Euro (€)
| Forward PE: | 25.641 |
|---|---|
| Trailing PE: | 21.2661 |
| Price-to-Book MRQ: | 3.2676 |
| Price-to-Sales TTM: | 3.2816 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 12084 |